Ĥ·Ö×Ó,membrane molecularÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÔÙ¹£×è,recurrent obstructionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Tϸ°ûÃâÒßÇòµ°°×¼°ð¤µ°°×Óò·Ö×Ó4,T cells immunoglobulin-and mucin-domain-containing molecule 4Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈË±íÆ¤Éú³¤Òò×ÓÊÜÌå-2,human epithelial growth factor receptor-2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« È˽᳦°©HT-29ϸ°û,colon cancer HT-29 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö×ªÒÆÏà¹Ø»ùÒòµ°°×,Tumor metastasis-associated gene proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ°°×ÎÄ¿â,Protein libraryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÊÖÊõÄÍÊÜÐÔ,Operation toleranceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« θµ×°©,gastricus fundus carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« p33ING1µ°°×,p33ING1 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈËÖØ×éµ°°×,human recombination proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ÎÔÙÉúÁ×Ëáø,phosphatases in regenerating liverÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ȱÑõÓÕµ¼Òò×Ó2»ùÒò,endothelia PAS domain protein 1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÎÂÈȹàÏ´,Thermotherapy lavageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È˽᳦°©Ï¸°ûÖêLS174,Human colon carcinoma cell line LS174Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ñ×Ö¢ºÍÓªÑøÔ¤ºóÖ¸Êý,Prognostic inflammatory and nutritional indexÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸Æ-¸Æµ÷ËØÒÀÀµÐÔµ°°×¼¤Ã¸,Ca2+-calmodulin dependent protein kinaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÅßÌ¥¸ÎǰÌåϸ°û,Fetal hepatic progenitor cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« pcNICDÔØÌå,pcNICD vectorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« p120-cateninµ°°×,p120-catenin proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Ç¹¦ÄÜÐÔÒȵºÏ¸°ûÁö,nonfunctional islet-cell tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« FOXOת¼Òò×Ó,FOXO transcription factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÓÐË¿·ÖÁÑ·Ä´¸Ìå¼à²âµã,mitotic spindle checkpointÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈËÕý³£×éÖ¯,human normal tissuesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« MMP2»ùÒò,MMP2 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« MPOG-463A»ùÒò¶à̬ÐÔ,Myeloperoxidase G-463A Gene PolymorphismÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 1ºÅȾɫÌåÀ©ÔöÇø,amplification district of chromosome 1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½×ÌÝ×ªÒÆÄ£ÐÍ,Stepwise metastasis modelÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« SW1116ϸ°ûÖê,SW1116 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö±³¦Íѳö¼¼Êõ,Prolapsing techniqueÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÇàÄê½á³¦°©,young colon carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾Ûµç½âÖʸ´ºÏ·¨,Polyelectrolyte complexationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ùÒòÖ×Áö±ê¼ÇÎï,gene tumor markersÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ê®¶þÖ¸³¦ÈéÍ·ÄÚÉúÐÔÏÙÁö,Endogenous adenoma of the duodenal papillaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« СÊó˫΢Ìå2»ùÒò,Murine double minute 2 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½áÖ±³¦°©/ÍíÆÚ,Colorectal cancer/advancedÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÔçÆÚµòÍö,early apoptosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÀÒ°±Ëáµ°°×¼¤Ã¸ÊÜÌåEphB2,Receptor tyrosine kinase EphB2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« PEBP1»ùÒò,PEBP1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ¨µÀ¶ñÐÔ¹£×è,malignant biliary obstructiveÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« EC1ϸ°û,EC1 cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´óÌåÖ×Áö,gross tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÉÃ×»¯ÁÆÒ©Îï,nanochemotherapy drugÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« III¶Îµ¨³¦ÎǺÏ,III cholangioenterica tomosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ÎÃŵ¨¹Ü,in ahepatic ductÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 賦µÀÍâ¼äÖÊÖ×Áö,Extra-gastrointestonal stromal tumersÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼ÁÁ¿±ä»¯,dosage changeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾±¶Î¼°ÐØÉ϶Îʳ¹Ü°©,cervical and upper thoracic esophageal cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô¶ÇÐÔµ,Distal MarginÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾­Æ¤¸Î´©´Ìµ¨¹ÜÄÚÍâÒýÁ÷Êõ,Percutaneous transhepatic catheter drainageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« òÚò¼ÌáȡҺ,extract of centipedeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖÐÒ©Äæ×ª,Chinese medicine to reverseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 賦ÁܰÍÁö,Gastrointastinal lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ÎÍ⹩Ѫ¶¯Âö,Extrahepatic feeding arteriesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½ðÜñÂó¿¹Ö×ÁöÌáÈ¡Îï,Fagopyrurn cymosum Meisn extract(FR)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« MICA-NKG2Dϵͳ,MICA-NKG2D ligand-receptor systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖÐÐÔÁ£Ï¸°ûÓëÁܰÍϸ°û±ÈÖµ,neutrophil-to-lymphocyte ratioÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸¹Ä¤²¥É¢ÐÔÆ½»¬¼¡Áö²¡,leiomyomatosis peritonealis disseminataÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« θ°©ÁöÖêMKN45,gastric cancer cell strain MKN45Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂÌɫӫ¹â¹²±í´ïÔØÌå,EGFP expression vectorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ªÒÆÐԽ᳦°©,Metastatic colon carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈéÃÓ³Ø,alveus ampullescensÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ÄÁ¼Folfox·½°¸,modified Folfox regimenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûϵSHEE,cell line SHEEÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶à»Ø²¨´Å¹²Õñ³ÉÏñ,multi-echo magnetic resonance imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« HERG1µ°°×,Herg 1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÉÃ×̿ʾ×Ù¼Á,carbon nano-particleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 賦¼äÖÊÁöÊõºó¸Î×ªÒÆ,liver metastatic gastrointestinal stromal tumors after radical resectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖÊÁ¿,qualityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ׼ȷ¶È,accuracyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ¨¹Ü°©,CholangiocarcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·¢Éú,OccurrenceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈéÍ·×´,papillaryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢ÇòÌå,microspheresÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÆÎÌï,PutianÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÒÏÙ°©,CystadenocarcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸¹°å,WebÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÊæÁÖËá,SulindacÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫ¹Üƽ»¬¼¡Ö¬·¾Áö,angiomyolipomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸Îĸϸ°ûÁö,HepatoblastomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ñõ»¯»¹Ô­Ã¸Àà,oxidoreductasesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Çú¸ñÁÐͪ,troglitazoneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ¨¹Üϸ°û°©,CholangiocarcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È©ÇâÒ¶Ëá,leucovorinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×®µ°°×,PaxillinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±ûÑõÄñÜÕ,ganciclovirÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ˨Èû»¯ÁÆ,ChemoembolizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö±³¦ÏµÄ¤,mesorectumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿ÉÇгýÐÔ,ResectabilityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ÅË¿Á£,CentromereÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍÑÑõ°ûÜÕ,deoxycytidineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¨Äª·ú,carmofurÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Îøµ°°±Ëá,selenomethionineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÎìµØÎô²¼,valdecoxibÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ººÉ,loadÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫ¹Ü¼¡Ö¬Áö,AngiomyolipomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉÏÆ¤¸Æð¤¸½ËØ,E-cadherinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼äÆ¤ËØ,mesothelinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸Î°©·¢Éú,hepatocarcinogenesisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ä×ÂüÇàÃ¹ËØ,WortmanninÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«